Abstract
Cystoscopy is considered the standard approach to the diagnostic workup of urinary symptoms. It has high sensitivity and specificity for papillary tumors of the bladder but low sensitivity and specificity for flat lesions. It is also expensive and may cause discomfort and complications. Urine cytology, in contrast, has the advantage of being a noninvasive test with high specificity but suffers from low sensitivity in low-grade and early-stage tumors, possibly due to the low number of exfoliated cells in urine. Numerous new noninvasive tests have been proposed. Among these, fluorescence in situ hybridization (FISH) has been studied for long time and in 2005 UroVysion Bladder Cancer Kit (UroVysion Kit) (Abbott/Vysis) received FDA approval for initial diagnosis of bladder carcinoma in patients with hematuria and subsequent monitoring for tumor recurrence in patients previously diagnosed with bladder cancer. The UroVysion Kit is designed to detect aneuploidy for chromosomes 3, 7, 17, and loss of the 9p21 locus by FISH in urine specimens from symptomatic patients, those with hematuria suspected of having bladder cancer. Here, the approach for FISH assay by using UroVysion Bladder Cancer kit according to manufacturer’s instructions is described.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Sokolova IA, Halling KC, Jenkins RB et al (2000) The development of a multitarget multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine. J Mol Diagn 2(3):116–123
Halling KC, King W, Sokolova IA et al (2000) A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. J Urol 164:1768–1775
Halling KC, King W, Sokolova IA et al (2002) A comparison of BTAstat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine. J Urol 167(5):2001–2006
Sarosdy MF, Schellhammer P, Bokinsky G et al (2002) Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. J Urol 168:1950–1954
Skacel M, Fahmy M, Brainard JA et al (2003) Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology. J Urol 169:2101–2105
Bravaccini S, Casadio V, Gunelli R et al (2011) Combining cytology, TRAP assay, and FISH analysis for the detection of bladder cancer in symptomatic patients. Ann Oncol 22(10):2294–2298
Goodison S, Rosser CJ, Urquidi V (2013) Bladder cancer detection and monitoring: assessment of urine-and blood-based marker tests. Mol Diagn Ther 17(2):71–84
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Bravaccini, S. (2021). Fluorescence In Situ Hybridization in Urine Samples (UroVysion Kit). In: Salvi, S., Casadio, V. (eds) Urinary Biomarkers. Methods in Molecular Biology, vol 2292. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-1354-2_4
Download citation
DOI: https://doi.org/10.1007/978-1-0716-1354-2_4
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-1353-5
Online ISBN: 978-1-0716-1354-2
eBook Packages: Springer Protocols